36 completed, 10 terminated, 7 active not recruiting, 4 recruiting. 62 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 62 | Completed 36, Terminated 10, Active not recruiting 7, Recruiting 4, Unknown 3, Withdrawn 2 |
| Phase 2 | 7 | Completed 6, Unknown 1 |
Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-11-13 |
| A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 34 | 2026-06-25 | 2026-08-26 |
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis dupilumab - Eosinophilic Esophagitis (EoE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 20 | 2025-11-10 | 2026-09-29 |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| SIM0718 Treatment of Asthma Clinical Study SIM0718 injection, SIM0718 injection of placebo - Asthma; Eosinophilic | Phase 3 | Active not recruiting | Simcere Pharmaceutical Co., Ltd | 418 | 2024-06-23 | 2026-11-09 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma Benralizumab, Placebo - Asthma | Phase 3 | Active not recruiting | AstraZeneca | 94 | 2023-04-05 | 2026-11-16 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 218 | 2022-12-29 | 2025-08-13 |
| Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Tezepelumab, Placebo - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | AstraZeneca | 368 | 2022-11-10 | 2026-10-30 |
| Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Depemokimab, Placebo - Hypereosinophilic Syndrome | Phase 3 | Active not recruiting | GlaxoSmithKline | 110 | 2022-09-06 | 2026-10-13 |
| Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538 - Eosinophilic Esophagitis | Phase 3 | Completed | Celgene | 367 | 2022-08-09 | 2026-04-06 |
| Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) Mepolizumab - Hypereosinophilic Syndrome | Phase 3 | Completed | GlaxoSmithKline | 16 | 2022-07-14 | 2026-07-06 |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial APT-1011, Placebo oral tablet - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 6 | 2021-09-30 | 2023-09-21 |
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE Budesonide - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | Dr. Falk Pharma GmbH | 308 | 2021-05-21 | 2026-08-28 |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Completed | Allakos Inc. | 94 | 2021-05-20 | 2024-01-02 |
Showing 20 of 62. Sign in to see all of them.
Eosinophilic Esophagitis (28) · Pulmonary Eosinophilia (21) · Asthma (14) · Hypereosinophilic Syndrome (8) · Esophageal Diseases (6) · Esophagitis (6) · Gastroenteritis (5) · Gastrointestinal Diseases (5) · Hypersensitivity (5) · Hematologic Diseases (4) · Leukocyte Disorders (4) · Eosinophilic enteropathy (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3)
Hemic and Lymphatic Diseases (62) · Hematologic Diseases (58) · Leukocyte Disorders (58) · Hypersensitivity, Immediate (40) · Immune System Diseases (40) · Hypersensitivity (38) · Digestive System Diseases (26) · Lung Diseases (24) · Respiratory Tract Diseases (24) · Gastroenteritis (23) · Gastrointestinal Diseases (23) · Esophageal Diseases (22) · Esophagitis (22) · Hypereosinophilic Syndrome (21)
mepolizumab (13) · benralizumab (8) · reslizumab (7) · Fluticasone (6) · Antibodies, Monoclonal, Humanized (5) · AK002 (4) · Budesonide (4) · APT-1011 (3) · dupilumab (3) · Endoscopy, Digestive System (2) · cendakimab (2) · Albendazole (1) · BID protein, human (1) · Esomeprazole (1) · Ketotifen (1)
GlaxoSmithKline (12) · AstraZeneca (8) · Teva Branded Pharmaceutical Products R&D, Inc. (5) · Allakos Inc. (4) · Areteia Therapeutics (4) · Dr. Falk Pharma GmbH (3) · Ellodi Pharmaceuticals, LP (3) · Regeneron Pharmaceuticals (3) · Shire (3) · Celgene (2) · Ception Therapeutics (2) · Children's Hospital Medical Center, Cincinnati (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Chiesi Farmaceutici S.p.A. (1) · Craig A. Friesen, MD (1)
United States (53) · Canada (24) · Germany (23) · Argentina (20) · United Kingdom (20) · France (18) · Italy (18) · Spain (18) · Poland (17) · Australia (16) · Belgium (15) · Netherlands (14) · Israel (13) · Brazil (12) · Japan (12)
Craig Paterson, MD (4) · Evan Dellon, MD, MPH (2) · Marc E Rothenberg, MD, PhD (2) · Ralph Mueller, PhD (2) · Alfredo J Lucendo, MD, PhD (1) · Amy D Klion, M.D. (1) · Amy Foxx-Orenstein, D.O. (1) · Christopher Brightling (1) · Craig A Friesen, MD (1)
PMID 39393433, PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 34182150, PMID 34389506, PMID 39735351, PMID 41749054, PMID 42031097, PMID 18344568, PMID 20810155, PMID 22111863, PMID 22206777, PMID 27018175, PMID 27056586, PMID 28395936, PMID 29949045, PMID 30922997, PMID 31047111, PMID 31251094, PMID 31507641, PMID 32721437, PMID 32956756, PMID 33887475, PMID 34098955, PMID 34158028, PMID 34172470, PMID 35283330, PMID 35493455, PMID 35568330, PMID 36091012, PMID 36546624, PMID 36863390, PMID 37064032, PMID 37660704, PMID 37718471, PMID 38010430, PMID 38050037, PMID 38771467, PMID 38924731, PMID 38924732, PMID 38940435, PMID 39384067, PMID 39631042, PMID 39694205, PMID 39777591
2023 (4), 2014 (3), 2019 (3), 2015 (2), 2016 (2), 2018 (2), 2017 (1), U54AI117804 (1)